A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-nave Patients with Higher Risk Myelodysplastic Syndrome
Sponsor: |
Forty Seven Inc. |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAT0000 |
U.S. Govt. ID: |
NCT04313881 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to compare the effects, both good and bad, of magrolimab in combination with azacitidine, to those of azacitidine in combination with placebo, to find out which is better for treating patients with MDS (Myelodysplastic Syndrome). Other purposes of this study include determining the quantity of magrolimab in the blood, aspects of your disease management (e.g. if you can have less frequent blood transfusions), your quality of life and the side effects magrolimab has on the body.
This study is closed
Investigator
Joseph Jurcic, MD
Are you at least 18 years old? |
Yes |
No |
Are you willing to undergo a blood transfusion if needed? |
Yes |
No |
Do you have untreated Myelodysplastic Syndrome (MDS)? |
Yes |
No |